دورية أكاديمية
2021 TSOC Expert Consensus on the Clinical Features, Diagnosis, and Clinical Management of Cardiac Manifestations of Fabry Disease.
العنوان: | 2021 TSOC Expert Consensus on the Clinical Features, Diagnosis, and Clinical Management of Cardiac Manifestations of Fabry Disease. |
---|---|
المؤلفون: | Hung CL; Division of Cardiology, Departments of Internal Medicine, MacKay Memorial Hospital, Taipei.; Institute of Biomedical Sciences, Mackay Medical College., Wu YW; Division of Cardiology, Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City.; School of Medicine, National Yang Ming Chiao Tung University, Taipei., Lin CC; Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital.; Department of Internal Medicine, College of Medicine, National Cheng Kung University, Tainan., Lai CH; Cardiovascular Center, Taichung Veterans General Hospital, Taichung., Jyh-Ming Juang J; Division of Cardiology, Department of Internal Medicine and Cardiovascular Center, National Taiwan University Hospital.; College of Medicine, National Taiwan University., Chao TH; Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital.; Department of Internal Medicine, College of Medicine, National Cheng Kung University, Tainan., Kuo L; Division of Cardiology, Taipei Veterans General Hospital, Taipei., Sung KT; Division of Cardiology, Departments of Internal Medicine, MacKay Memorial Hospital, Taipei., Wang CY; Division of Cardiology, Chang Gung Memorial Hospital, Linkou Medical Center.; School of Medicine, College of Medicine, Chang Gung University, Taoyuan.; Institute of Cellular and System Medicine, National Health Research Institutes, Zhunan., Wang CL; Division of Cardiology, Chang Gung Memorial Hospital, Linkou Medical Center.; School of Medicine, College of Medicine, Chang Gung University, Taoyuan., Chu CY; Division of Cardiology, Kaohsiung Medical University Hospital, Kaohsiung., Yu WC; School of Medicine, National Yang Ming Chiao Tung University, Taipei.; Division of Cardiology, Taipei Veterans General Hospital, Taipei., Hou CJ; Division of Cardiology, Departments of Internal Medicine, MacKay Memorial Hospital, Taipei.; Department of Medicine, Mackay Medical College, New Taipei City, Taiwan. |
المصدر: | Acta Cardiologica Sinica [Acta Cardiol Sin] 2021 Jul; Vol. 37 (4), pp. 337-354. |
نوع المنشور: | Journal Article; Review |
اللغة: | English |
بيانات الدورية: | Publisher: Taiwan Society of Cardiology Country of Publication: China (Republic : 1949- ) NLM ID: 101687085 Publication Model: Print Cited Medium: Print ISSN: 1011-6842 (Print) Linking ISSN: 10116842 NLM ISO Abbreviation: Acta Cardiol Sin Subsets: PubMed not MEDLINE |
أسماء مطبوعة: | Original Publication: Taipei : Taiwan Society of Cardiology |
مستخلص: | Fabry disease (FD) is an X-linked, rare inherited lysosomal storage disease caused by α-galactosidase A gene variants resulting in deficient or undetectable α-galactosidase A enzyme activity. Progressive accumulation of pathogenic globotriaosylceramide and its deacylated form globotriaosylsphingosine in multiple cell types and organs is proposed as main pathophysiology of FD, with elicited pro-inflammatory cascade as alternative key pathological process. The clinical manifestations may present with either early onset and multisystemic involvement (cutaneous, neurological, nephrological and the cardiovascular system) with a progressive disease nature in classic phenotype, or present with a later-onset course with predominant cardiac involvement (non-classical or cardiac variant; e.g. IVS4+919G>A in Taiwan) from missense variants. In either form, cardiac involvement is featured by progressive cardiac hypertrophy, myocardial fibrosis, various arrhythmias, and heart failure known as Fabry cardiomyopathy with potential risk of sudden cardiac death. Several plasma biomarkers and advances in imaging modalities along with novel parameters, cardiac magnetic resonance (CMR: native T1/T2 mapping) for myocardial tissue characterization or echocardiographic deformations, have shown promising performance in differentiating from other etiologies of cardiomyopathy and are presumed to be helpful in assessing the extent of cardiac involvement of FD and in guiding or monitoring subsequent treatment. Early recognition from extra-cardiac red flag signs either in classic form or red flags from cardiac manifestations in cardiac variants, and awareness from multispecialty team work remains the cornerstone for timely managements and beneficial responses from therapeutic interventions (e.g. oral chaperone therapy or enzyme replacement therapy) prior to irreversible organ damage. We aim to summarize contemporary knowledge based on literature review and the gap or future perspectives in clinical practice of FD-related cardiomyopathy in an attempt to form a current expert consensus in Taiwan. |
References: | J Am Coll Cardiol. 2016 Sep 6;68(10):1037-50. (PMID: 27585509) J Clin Med. 2020 Apr 14;9(4):. (PMID: 32295103) Genet Med. 2013 Dec;15(12):958-65. (PMID: 23703683) Mol Genet Metab. 2017 Nov;122(3):19-27. (PMID: 28947349) Mol Genet Metab. 2004 May;82(1):93-7. (PMID: 15110329) Mol Genet Metab. 2011 Nov;104(3):301-7. (PMID: 21795086) Am J Pathol. 2008 Jun;172(6):1482-90. (PMID: 18467700) Mol Genet Genomic Med. 2018 Apr 12;:. (PMID: 29649853) J Inherit Metab Dis. 2013 Sep;36(5):881-5. (PMID: 23109060) Eur Heart J. 2013 Jun;34(21):1587-96. (PMID: 23520186) Biomed Pharmacother. 2020 Nov;131:110779. (PMID: 33152937) J Med Genet. 2016 Jul;53(7):495-502. (PMID: 26993266) Clin Genet. 2016 Jan;89(1):44-54. (PMID: 25974833) J Cardiovasc Magn Reson. 2013 Oct 14;15:92. (PMID: 24124732) Hum Mutat. 2009 Oct;30(10):1397-405. (PMID: 19621417) Kidney Int. 2002 Dec;62(6):1933-46. (PMID: 12427118) PLoS One. 2017 Aug 1;12(8):e0182379. (PMID: 28763515) Br Heart J. 1992 Sep;68(3):323-5. (PMID: 1389767) PLoS One. 2017 Mar 15;12(3):e0173358. (PMID: 28296917) Am J Kidney Dis. 2008 May;51(5):767-76. (PMID: 18436087) Kidney Int. 2002 Jan;61(1):249-55. (PMID: 11786107) J Med Genet. 2001 Nov;38(11):750-60. (PMID: 11694547) Lancet. 2005 Nov 19;366(9499):1794-6. (PMID: 16298216) Eur J Echocardiogr. 2011 Sep;12(9):671-7. (PMID: 21810826) Eur J Pediatr. 2003 Nov;162(11):767-72. (PMID: 14505049) PLoS One. 2012;7(5):e33743. (PMID: 22574107) Circ Cardiovasc Genet. 2009 Oct;2(5):450-6. (PMID: 20031620) J Am Soc Hypertens. 2016 Jan;10(1):70-80. (PMID: 26850524) Clin Exp Nephrol. 2018 Aug;22(4):843-849. (PMID: 29288396) Heart. 2010 Dec;96(23):1915-9. (PMID: 20965976) Heart. 2012 Oct;98(19):1442-8. (PMID: 22865865) Eur Heart J. 2011 Jun;32(12):1542-50. (PMID: 21447510) J Am Heart Assoc. 2016 May 31;5(6):. (PMID: 27247331) Kidney Int. 1978 Mar;13(3):223-35. (PMID: 418264) Mol Genet Metab. 2017 Jun;121(2):157-161. (PMID: 28495078) Orphanet J Rare Dis. 2010 Nov 22;5:30. (PMID: 21092187) J Intern Med. 2013 Oct;274(4):331-41. (PMID: 23586858) J Hum Genet. 2016 Sep;61(9):775-80. (PMID: 27225851) J Med Genet. 2001 Nov;38(11):769-75. (PMID: 11732485) J Inherit Metab Dis. 2018 Mar;41(2):209-219. (PMID: 29143201) Mol Ther Methods Clin Dev. 2020 Jul 09;18:607-619. (PMID: 32775495) Acta Paediatr Suppl. 2002;91(439):21-7. (PMID: 12572838) Circ Cardiovasc Imaging. 2019 Apr;12(4):e008424. (PMID: 30943767) JACC Cardiovasc Imaging. 2019 Aug;12(8 Pt 2):1673-1683. (PMID: 29778854) Heart. 2011 Mar;97(6):485-90. (PMID: 21270075) Heart. 2007 Apr;93(4):528-35. (PMID: 17401074) Curr Opin Nephrol Hypertens. 2005 Mar;14(2):87-95. (PMID: 15687833) J Nephrol. 2016 Dec;29(6):791-797. (PMID: 26842625) Mol Genet Metab. 2020 Feb;129(2):150-160. (PMID: 31519519) Eur Heart J Cardiovasc Imaging. 2017 Sep 1;18(9):1034-1040. (PMID: 27590835) Echocardiography. 2017 Apr;34(4):504-510. (PMID: 28256008) J Med Genet. 2018 May;55(5):351-358. (PMID: 29437868) Circ Res. 2016 Jul 8;119(2):277-99. (PMID: 27390332) Stroke. 2015 Jan;46(1):302-13. (PMID: 25492902) Genet Med. 2009 Nov;11(11):790-6. (PMID: 19745746) J Am Coll Cardiol. 2002 Nov 6;40(9):1668-74. (PMID: 12427421) J Am Soc Nephrol. 2017 May;28(5):1631-1641. (PMID: 27979989) J Inherit Metab Dis. 2020 Sep;43(5):908-921. (PMID: 32083331) J Am Soc Echocardiogr. 2017 Mar;30(3):282-291. (PMID: 28069318) Biochim Biophys Acta. 2011 Jan;1812(1):70-6. (PMID: 20851180) Eur J Heart Fail. 2020 Jul;22(7):1076-1096. (PMID: 32640076) J Am Heart Assoc. 2018 Nov 6;7(21):e009098. (PMID: 30571380) J Inherit Metab Dis. 2014 Nov;37(6):1013-22. (PMID: 24850378) Expert Opin Biol Ther. 2019 Jul;19(7):655-670. (PMID: 31056978) Am J Cardiol. 2012 Feb 15;109(4):587-93. (PMID: 22105784) Circ Cardiovasc Imaging. 2019 Dec;12(12):e009430. (PMID: 31826677) Heart. 2006 Mar;92(3):357-60. (PMID: 16085718) PLoS One. 2012;7(4):e36373. (PMID: 22558451) PLoS One. 2014 Mar 13;9(3):e91757. (PMID: 24626231) Orphanet J Rare Dis. 2014 Jul 22;9:111. (PMID: 25047006) Circulation. 2003 Apr 22;107(15):1978-84. (PMID: 12668521) Mol Genet Metab. 2018 Feb;123(2):148-153. (PMID: 28728877) Circ Cardiovasc Imaging. 2013 Sep;6(5):637-45. (PMID: 23922004) Heart. 2011 Dec;97(23):1957-60. (PMID: 21890869) J Am Soc Echocardiogr. 2013 Dec;26(12):1407-14. (PMID: 24125876) Eur Heart J. 2007 May;28(10):1228-35. (PMID: 17483538) J Am Soc Nephrol. 2018 Dec;29(12):2879-2889. (PMID: 30385651) J Am Coll Cardiol. 2021 Feb 23;77(7):922-936. (PMID: 33602475) Curr Gene Ther. 2019;19(1):3-5. (PMID: 31190639) Mol Genet Metab Rep. 2019 Feb 06;19:100454. (PMID: 30775256) J Am Coll Cardiol. 2016 Dec 13;68(23):2554-2563. (PMID: 27931613) Nephron. 2015;129(1):16-21. (PMID: 25531941) Eur Heart J. 2014 Oct 14;35(39):2733-79. (PMID: 25173338) ESC Heart Fail. 2020 Jun;7(3):1331-1337. (PMID: 32347011) Mol Genet Metab. 2019 Feb;126(2):169-182. (PMID: 30594474) J Med Genet. 2015 Apr;52(4):262-8. (PMID: 25596309) J Cardiovasc Magn Reson. 2014 Dec 05;16:99. (PMID: 25475749) N Engl J Med. 1995 Aug 3;333(5):288-93. (PMID: 7596372) JAMA. 1999 Jan 20;281(3):249-54. (PMID: 9918480) Mol Genet Metab. 2018 Apr;123(4):416-427. (PMID: 29530533) J Neurol Sci. 2007 Jun 15;257(1-2):258-63. (PMID: 17362993) Eur J Clin Invest. 2004 Mar;34(3):236-42. (PMID: 15025684) Echocardiography. 2013 Jan;30(1):88-105. (PMID: 23297852) J Inherit Metab Dis. 2008 Feb;31(1):117-23. (PMID: 18172744) J Med Genet. 2018 Apr;55(4):261-268. (PMID: 29330335) Heart. 2009 Jul;95(13):1103-7. (PMID: 19372091) Circ Res. 1988 Feb;62(2):191-5. (PMID: 2962782) Front Cardiovasc Med. 2016 Mar 24;3:7. (PMID: 27047943) J Am Soc Nephrol. 2013 Jan;24(1):137-48. (PMID: 23274955) Acta Paediatr Suppl. 2005 Mar;94(447):24-7; discussion 9-10. (PMID: 15895708) Stem Cell Reports. 2019 Aug 13;13(2):380-393. (PMID: 31378672) Int J Mol Sci. 2020 Oct 29;21(21):. (PMID: 33138098) Europace. 2018 Sep 1;20(FI2):f153-f161. (PMID: 29045633) JACC Cardiovasc Imaging. 2019 Jul;12(7 Pt 1):1230-1242. (PMID: 31272606) Circulation. 2009 May 19;119(19):2561-7. (PMID: 19414635) J Am Soc Echocardiogr. 2013 Dec;26(12):1415-23. (PMID: 24094560) Lancet. 2008 Oct 18;372(9647):1427-35. (PMID: 18940466) Stroke. 2010 Jan;41(1):78-81. (PMID: 20007919) Clin Kidney J. 2018 Nov 14;12(1):65-70. (PMID: 30906541) Eur Heart J. 2013 Mar;34(11):802-8. (PMID: 22736678) Am J Cardiol. 2013 Jan 1;111(1):111-7. (PMID: 23040658) Prog Cardiovasc Dis. 2010 Jan-Feb;52(4):326-35. (PMID: 20109602) |
فهرسة مساهمة: | Keywords: Cardiac magnetic resonance (CMR); Cardiac variant; Chaperone; Enzyme replacement therapy (ERT); Fabry disease (FD); Globotriaosylceramide (Gb3); Globotriaosylsphingosine (Lyso-Gb3); IVS4+919G>A; α-galactosidase A (GLA) gene |
تواريخ الأحداث: | Date Created: 20210714 Latest Revision: 20210715 |
رمز التحديث: | 20221213 |
مُعرف محوري في PubMed: | PMC8261701 |
DOI: | 10.6515/ACS.202107_37(4).20210601A |
PMID: | 34257484 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1011-6842 |
---|---|
DOI: | 10.6515/ACS.202107_37(4).20210601A |